Subscribe free to our newsletters via your
. Military Space News .




MILTECH
"Artificial Spleen" Could Increase Survival Odds for Future Sepsis Patients
by Staff Writers
Washington DC (SPX) Sep 16, 2014


As reported in Nature Medicine, DARPA's Dialysis-Like Therapeutics (DLT) program has engineered a novel device inspired by the human spleen that quickly filters from human blood many of the microbes and toxins that can trigger sepsis-a life-threatening over-reaction by the immune system to infection. The technology could greatly advance future sepsis treatments and lead to increased survival of a condition that afflicts 18 million people a year worldwide and kills between 30 and 50 percent of them.

Sepsis - a life-threatening over-reaction by the immune system to infection - afflicts 18 million people a year worldwide and kills between 30 and 50 percent of them. Sepsis poses a significant threat to warfighters who suffer combat injuries that predispose them to infection.

Antibiotics can kill sepsis-inducing microbes but their overuse is contributing to the threat of drug-resistant microbes and they don't neutralize the toxins that some pathogens leave behind. Commercial dialysis equipment can remove toxins from the blood but is not built for routine use in theater.

DARPA's Dialysis-Like Therapeutics (DLT) program seeks to develop integrated, portable and ruggedized technology that would enable widespread deployment of dialysis treatment to fight sepsis. The program recently tested a novel prototype that could greatly advance sepsis treatment and lead to increased survival of future sepsis patients.

As reported in Nature Medicine, the DLT program successfully demonstrated one of the first technologies for pathogen removal via blood filtration. With a design inspired by the human spleen, the shoebox-sized prototype removes many of the microbes and toxins that can trigger sepsis.

"Sepsis is a massive problem for both civilian and military healthcare, which is why DARPA set out to develop more effective and portable technologies for sepsis treatment," said U.S.Army Col. Matt Hepburn, DARPA program manager.

"Our 'artificial spleen' prototype shows a promising new way to fight sepsis more quickly and thoroughly. The technology is also small and light, and usable either on its own or with commercial dialysis equipment."

Eventually, Hepburn added, DLT could preclude the need to fully identify a bacterium or test whether it is antibiotic resistant-which can take hours or days-before beginning treatment. "We're hopeful that this new technology could give doctors new tools to save lives in the future," he said.

The DLT prototype is designed to work outside the body like a traditional dialysis machine. Blood is funneled from a patient's veins into the device, where it is cleaned before returning to the body. The approach is similar to that used by the human spleen, which removes pathogens and dead cells from the blood by filtering it through a series of tiny interwoven blood channels.

In the DLT device, a series of microfluidic channels take the place of blood vessels. Two adjacent hollow channels-one containing flowing blood, the other a saline solution-connect to each other by a series of slits.

As blood enters the device, it is mixed with tiny magnetic beads 128 nanometers in diameter that are coated with a genetically engineered version of a natural immune system protein called mannose binding lectin (MBL). Sepsis-inducing microbes and toxins stick to the beads, which a magnet pulls through the slits and into the saline solution for collection and removal. The cleaned blood is then re-infused into the patient.

DLT's breakthrough capabilities capitalize on the structure of MBL, which has a branch-like "head" and a stick-like "tail." In the body, the head binds to specific sugars on the surfaces of harmful microbes and toxins, and the tail attaches to immune-system proteins that catalyze their destruction.

Sometimes, however, the tails attach to other immune system proteins, which activate an autoimmune response that can lead to blood clotting and organ damage. The DLT team used genetic engineering tools to create an altered version of MBL whose tail does not bind to the problematic, auto-immune-triggering proteins.

The DLT team first tested its blood-cleaning system in the laboratory using human blood spiked with pathogens. A single device bound and removed more than 90 percent of key sepsis pathogens.

The team next tested the device using rats infected with two pathogens (E. coli and S. aureus) along with bacterial toxins-a microbial cocktail mimicking those seen in the bloodstreams of human sepsis patients. The prototype removed about 90 percent of the bacteria and toxins from the rats' bloodstreams within five hours.

Going forward, DARPA plans to continue development of component technologies to mitigate sepsis and then combine those component technologies into an integrated system. Subsequent trials would then seek to demonstrate the safety and efficacy of the integrated DLT device and provide crucial evidence to support an eventual application to the U.S. Food and Drug Administration for clinical trials with human volunteers.

.


Related Links
DARPA
The latest in Military Technology for the 21st century at SpaceWar.com






Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.

Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle




Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News





MILTECH
Exelis receives new order for night vision goggles
Roanoke, Va. (UPI) Sep 14, 2014
More Generation 3 night vision equipment has been ordered from Exelis, with deliveries to occur from late this year and early into 2015. The order, under a 2011 indefinite-delivery/indefinite-quantity OMNI VIII contract, carries a value of $8 million, the technology company said. "As a cost-effective manufacturer of high-reliability night vision goggles, Exelis continues to provi ... read more


MILTECH
Raytheon providing ongoing support for Patriot air defense system

Israel, US test upgraded Arrow 2 missile interceptor

INFORMS Study on Iron Dome Asks: What Was its Impact?

Raytheon AI3 missile intercepts first cruise missile target

MILTECH
Raytheon announces full-rate production of Talon rocket

China shows off new missile test on primetime television

Diehl delivers 4,000th production IRIS-T missile to Sweden

Turkey in talks with France over missile purchase: Erdogan

MILTECH
Boeing may assist Sky-Watch in UAV development

Nothrop to provide Air Force with more Global Hawk drones

Helicopter-Type UAVs May Appear in Russian Navy in One Year

Unmanned vehicles tested in Arctic

MILTECH
Harris Corporation supply Falcon III RF-340M radios to U.S. military

Middle East entity orders Harris tactical radios

FirstNet-related Tactical LTE Communications System at Urban Shield Exercise

Intelsat General Extends Contract to Provide Satellite Capacity to Forces in Afghanistan

MILTECH
"Artificial Spleen" Could Increase Survival Odds for Future Sepsis Patients

Joint venture bid for Britain's Defense Support Group

Lockheed Martin partners with Saudi firm for Sniper ATP support facility

Exelis receives new order for night vision goggles

MILTECH
Airbus to restructure defence division, sell off units

Israeli arms sale to Ukraine blocked: report

'All bases covered' in coalition bid to crush IS

Netherlands ups defence spending in wake of downed MH17

MILTECH
Dalai Lama calls inter-faith meeting in India to counter violence

China's Xi pledges closer defence ties with Sri Lanka

Russia to deploy reinforcements to Crimea area: minister

China's Xi visits India, sets tone for future relations

MILTECH
Decoding the role of water in gold nanocatalysis

Magnetic nanocubes self-assemble into helical superstructures

Nanotechnology aids in cooling electrons without external sources

Nano-pea pod model widens electronics applications




The content herein, unless otherwise known to be public domain, are Copyright 1995-2014 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement All images and articles appearing on Space Media Network have been edited or digitally altered in some way. Any requests to remove copyright material will be acted upon in a timely and appropriate manner. Any attempt to extort money from Space Media Network will be ignored and reported to Australian Law Enforcement Agencies as a potential case of financial fraud involving the use of a telephonic carriage device or postal service.